Trastuzumab (Herceptin) has revolutionised the care of HER2-positive (HER2+) early breast cancer* and is the standard treatment for tumours larger than 1cm. By contrast, most small (⤠1cm) breast cancers have a favourable prognosis and are widely believed not to benefit from adjuvant treatment (treatment given in addition to primary therapy)...
More...